Prague 10

• A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimil … Not authorised
  2022-501361-44-00 5 Adult patients of either gender with active moderate to severe rheumat
• Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis Not authorised
  2023-503522-40-00 4 Atopic Dermatitis
• Study to Evaluate the Efficacy and Safety of ATI-045 in Atopic Dermatitis Not authorised
  2024-520302-19-00 4 Atopic dermatitis
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso … Pending
  2025-522586-30-00 5 Psoriatic Arthritis
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Recruiting
  2025-523202-32-00 5 2026-02-26 Major Depressive Disorder
• Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting
  2024-519423-24-00 5 2025-10-07 Major Depressive Disorder
• A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Recruiting
  2024-519795-11-00 4 2025-10-06 Atopic Dermatitis
• A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Ad … Recruiting
  2025-521240-37-00 4 2025-09-11 Major Depressive Disorder (MDD), with or without Anxious Distress
• Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting
  2024-520107-12-00 5 2025-09-03 Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
• An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting
  2024-511166-36-00 5 2025-06-13 Moderate to Severe Plaque Psoriasis
• A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c … Recruiting
  2023-505606-42-00 5 2024-10-15 Head and Neck Squamous Cell Carcinoma (HNSCC)
• Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re … Recruiting
  2023-504918-29-00 5 2024-08-22 Hormone receptor positive breast cancer
• An Open label, Safety Clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia Recruiting
  2023-509518-12-01 4 2024-04-16 Tardive dyskinesia
• A trial to learn how effective and safe odronextamab is compared to standard of care for adult participants with previously treated aggressi … Recruiting
  2022-502783-21-00 5 2024-02-20 B-Cell Non-Hodgkin's Lymphoma
• A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che … Recruiting
  2022-502660-20-00 5 2024-01-23 Follicular lymphoma
• Clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia with open-label Part I and randomized, d … Recruiting
  2024-516852-17-00 4 2023-11-13 Tardive dyskinesia
• Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting
  2022-500544-38-00 5 2023-06-05 Advanced Breast Cancer
• (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Recruiting
  2022-501427-24-00 4 2023-04-25 Nonadvanced Systemic Mastocytosis
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 5 2023-01-09 Severe viral lung infections
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica … Recruiting
  2023-506548-18-00 10 2022-11-10 Dermatitis atopic
• Phase 3 Trial of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation Recruiting
  2022-503012-16-00 5 2022-07-20 Patients on treatment with Factor Xa Inhibitor needing for an urgent i
• Rituximab in patients with ST-elevation myocardial infarction. A phase 2 placebo-controlled randomized clinical trial. Recruiting
  2022-501893-21-00 4 2022-05-03 Acute myocardial infarction

Showing 1–24 of 165 trials